The estimated Net Worth of Gwendolyn Binder is at least $1.35 Milion dollars as of 19 January 2024. Gwendolyn Binder owns over 11,000 units of Cabaletta Bio Inc stock worth over $132,060 and over the last 5 years he sold CABA stock worth over $0. In addition, he makes $1,221,080 as Executive Vice President i Science & Technology at Cabaletta Bio Inc.
Sign up
Gwendolyn Scholl CABA stock SEC Form 4 insiders trading
Gwendolyn has made over 10 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 11,000 units of CABA stock worth $11,110 on 19 January 2024.
The largest trade he's ever made was exercising 22,000 units of Cabaletta Bio Inc stock on 19 May 2023 worth over $22,220. On average, Gwendolyn trades about 8,667 units every 31 days since 2019. As of 19 January 2024 he still owns at least 31,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Gwendolyn Binder stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gwendolyn Binder-Scholl biography
Dr. Gwendolyn Knowlton Binder-Scholl Ph.D. serves as Executive Vice President, Science & Technology of the Company. Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she initially established and led capabilities in manufacturing, correlative science, compliance, regulatory and clinical operations, to enable the transfer of certain T cell receptor clinical programs from the Translational Research Program at the University of Pennsylvania and vector and cell manufacturing. She later went on to establish the internal translational sciences, and manufacturing and quality teams and oversaw the planning and execution of an onsite manufacturing facility. Once the manufacturing was secure, she assumed leadership of the research organization. Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she participated in multiple engineered T cell therapy clinical programs in HIV and oncology including the data generation and IND drafting for CART 19 under the leadership of Drs. Carl June and Michael Milone. Prior to that, she was the director of scientific affairs at VIRxSYS Corporation. Dr. Binder received her Ph.D. from the Johns Hopkins University School of Medicine and her B.A. from Wells College.
What is the salary of Gwendolyn Scholl?
As the Executive Vice President i Science & Technology of Cabaletta Bio Inc, the total compensation of Gwendolyn Scholl at Cabaletta Bio Inc is $1,221,080. There are 2 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of $1,528,630.
How old is Gwendolyn Scholl?
Gwendolyn Scholl is 45, he's been the Executive Vice President i Science & Technology of Cabaletta Bio Inc since 2019. There are 11 older and 3 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
What's Gwendolyn Scholl's mailing address?
Gwendolyn's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Insiders trading at Cabaletta Bio Inc
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... oraz James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
What does Cabaletta Bio Inc do?
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
What does Cabaletta Bio Inc's logo look like?
Complete history of Gwendolyn Binder stock trades at Cabaletta Bio Inc
Cabaletta Bio Inc executives and stock owners
Cabaletta Bio Inc executives and other stock owners filed with the SEC include:
-
Anup Marda,
Chief Financial Officer -
Steven Nichtberger,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Gwendolyn Binder-Scholl,
Executive Vice President, Science & Technology -
Dr. Steven A. Nichtberger M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Steven A. Nichtberger,
Co-Founder, Chairman, CEO & Pres -
Dr. David J. Chang M.D., M.P.H.,
Chief Medical Officer -
Dr. Gwendolyn K. Binder,
Exec. VP of Science & Technology -
Richard Henriques,
Independent Director -
Catherine Bollard,
Independent Director -
Mark Simon,
Independent Director -
Brian Daniels,
Independent Director -
David Chang,
Chief Medical Officer -
J. Brian Stalter,
General Counsel -
Michael Gerard J.D.,
Gen. Counsel & Sec. -
Heather Harte-Hall M.Sc.,
Chief Compliance Officer -
Michael Gerard,
Gen. Counsel -
Dr. Samik Basu M.D.,
Chief Scientific Officer -
Martha O'Connor,
Chief HR Officer -
J. Brian Stalter J.D.,
Gen. Counsel -
Dr. Aimee Payne M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Dr. Michael C. Milone M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Anup Marda M.B.A.,
Chief Financial Officer -
Shawn Tomasello,
-
Scott C. Brun,
-
Gwendolyn Binder,
See Remarks -
Arun Das,
Chief Business Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt Iv, ...,
-
Ventures V, L.P.5 Am Opport...,
-
Michael Gerard,
General Counsel